Physician profile
Melissa Sepe
NPI 1396222824
$1,962.12
in general payments reported to CMS, 2019-2025
14 companies · $115 in 2025
The $115 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $510 · 2022: $497 · 2023: $297 · 2024: $543 · 2025: $115.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $758.99 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $260.60 | 2021-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $237.63 | 2024 | Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $145.00 | 2021-2023 | Jardiance |
| Abbvie INC. | $133.04 | 2021-2023 | |
| Lilly USA, LLC | $111.14 | 2021-2023 | Mounjaro, Jardiance, Trulicity |
| Pfizer INC. | $83.83 | 2022-2024 | |
| Glaxosmithkline, LLC. | $59.76 | 2023-2024 | Shingrix, Arexvy |
| Renalytix Ai, INC. | $46.07 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $32.61 | 2022 | |
| Janssen Pharmaceuticals, INC | $31.95 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.64 | 2022 | |
| Medtronic, INC. | $16.07 | 2023 | Intellis Adaptivestim |
| Merck Sharp & Dohme LLC | $15.79 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Sepe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.